Nanjing, China

Zheng Fu

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Nanjing University. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Zheng Fu. Retrieved from https://idiyas.com/inventor/zheng-fu-wd8v412r

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Zheng Fu: Innovator in Cancer Treatment

Introduction

Zheng Fu is a prominent inventor based in Nanjing, China. He has made significant contributions to the field of cancer treatment through his innovative research and development. His work focuses on the use of multi-targeted siRNA, which has the potential to revolutionize cancer therapies.

Latest Patents

Zheng Fu holds a patent for "MULTI-TARGETED siRNA FOR TREATING CANCERS." This patent represents a crucial advancement in the fight against cancer, showcasing his commitment to improving patient outcomes through scientific innovation. He has 1 patent to his name.

Career Highlights

Zheng Fu is affiliated with Nanjing University, where he conducts his research and collaborates with other experts in the field. His academic background and dedication to research have positioned him as a leading figure in cancer treatment innovations.

Collaborations

Zheng Fu has worked alongside talented colleagues, including Chenyu Zhang and Xi Chen. Their collaborative efforts have contributed to the advancement of cancer treatment methodologies and have fostered a productive research environment.

Conclusion

Zheng Fu's work in developing multi-targeted siRNA for treating cancers highlights his innovative spirit and dedication to improving healthcare. His contributions to the field are invaluable and pave the way for future advancements in cancer therapies.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…